Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China.
Front Endocrinol (Lausanne). 2021 May 20;12:636175. doi: 10.3389/fendo.2021.636175. eCollection 2021.
Diabetes is a highly prevalent metabolic disease that has emerged as a global challenge due to its increasing prevalence and lack of sustainable treatment. Diabetic kidney disease (DKD), which is one of the most frequent and severe microvascular complications of diabetes, is difficult to treat with contemporary glucose-lowering medications. The gut microbiota plays an important role in human health and disease, and its metabolites have both beneficial and harmful effects on vital physiological processes. In this review, we summarize the current findings regarding the role of gut microbial metabolites in the development and progression of DKD, which will help us better understand the possible mechanisms of DKD and explore potential therapeutic approaches for DKD.
糖尿病是一种高发的代谢性疾病,由于其患病率不断上升且缺乏可持续的治疗方法,已成为全球性挑战。糖尿病肾病(DKD)是糖尿病最常见和最严重的微血管并发症之一,目前使用的降糖药物很难对此进行治疗。肠道微生物群在人类健康和疾病中发挥着重要作用,其代谢产物对重要的生理过程既有有益的影响,也有有害的影响。在这篇综述中,我们总结了目前关于肠道微生物代谢产物在 DKD 发生和发展中的作用的研究结果,这将有助于我们更好地理解 DKD 的可能机制,并探索 DKD 的潜在治疗方法。